Oxaliplatin

Research use only, not for human use.

A platinum-based antineoplastic agent that works by blocking the duplication of DNA; forms both inter- and intra-strand cross links in DNA, prevents DNA replication and transcription, causing cell death.

A platinum-based antineoplastic agent that works by blocking the duplication of DNA; forms both inter- and intra-strand cross links in DNA, prevents DNA replication and transcription, causing cell death.Chemotherapeutic Agents Approved(In Vitro):Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis.Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC).Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively.(In Vivo):Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth.

Cell Viability Assay Cell Line:HCC, HCCLM3 and Hep3B cells Concentration:24, 48 and 72 hours Incubation Time:2, 4, 8, 16, 32, 64 and 128 μM Result:Decreased cell viability in a dose- and time-dependent manner.Cell Cycle AnalysisCell Line:HCCLM3 and Hep3B cells Concentration:10 μM Incubation Time:24 hours Result:Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).Cell Cycle Analysis Cell Line:HCCLM3 cells Concentration:10 μM Incubation Time:48 hours Result:Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.

Animal Model:Nude mice Dosage:5 and 10 mg/kg Administration:Intraperitoneal injection; for 32 days Result:Reduced tumor volume in HCCLM3 tumor xenografts.

Dacplat | Eloxatin? | Elplat | Lipoxal | NSC 266046 | RP 54780

Cell Cycle/DNA Damage

DNA Alkylator

DNAsynthesis

Cancer

Chemotherapeutic

61825-94-3

397.2917

C8H14N2O4Pt

>98% (HPLC)

DMSO: 32 mg/mL (Need ultrasonic)

O=C1[O-][Pt+2]2([O-]C1=O)[NH2]C3CCCCC3[NH2]2

Platinum, [(1R,2R)-1,2-cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]-, (SP-4-2)-

(-20℃)

With Ice Pack

≥ 2 years